CONSORTIUM FOR GENOMIC TECHNOLOGIESSOCIETA BENEFIT SRL

Their core work

Cogentech is a Milan-based genomics technology company (società benefit) that develops molecular diagnostic tools for cancer detection, with a core focus on liquid biopsy — analyzing circulating cell-free nucleic acids extracted from blood and other biofluids rather than invasive tissue sampling. Their technical signature is the use of peptide nucleic acids (PNAs) as high-specificity molecular probes integrated into microsphere-based sensor platforms for detecting cancer biomarkers. In diaRNAgnosis, they contribute to building a direct profiling platform for circulating cell-free RNA, targeting prostate and testicular cancers. As a third party in the ERC Advanced Grant project TARGET, they extend their genomics capabilities into the cancer immunology domain, supporting research on DNA repair pathways and anti-tumour immunity.

What they specialise in

How they've shifted over time

With both projects beginning in 2021, there is no meaningful chronological evolution to trace — the keyword split between "early" and "recent" reflects two different concurrent projects rather than a shift over time. Taken together, the two projects reveal a dual specialisation: a diagnostics-technology track (diaRNAgnosis — PNAs, microspheres, liquid biopsy) and a broader cancer biology track (TARGET — immunotherapy, DNA repair, bioinformatics). If there is a directional signal, it is that Cogentech is positioning itself as a genomics service provider that can feed both clinical diagnostics pipelines and fundamental oncology research programmes.

Cogentech appears to be expanding from a narrow diagnostic tool niche (liquid biopsy via PNA sensors) toward broader cancer biology support roles, suggesting future collaborations in immuno-oncology platforms and genomic biomarker discovery are plausible.

How they like to work

Cogentech has never led an H2020 project — their two participations are as a partner and as a third party, indicating they function as a specialist contributor rather than a consortium driver. Their involvement in an ERC Advanced Grant as a third party is notable: ERC grants are single-PI instruments, meaning Cogentech was brought in to provide a specific technical service or resource (likely genomic analysis capacity), not as a co-equal partner. This profile — deep specialist, low coordination overhead — makes them an efficient addition to consortia that need a genomics execution layer without the overhead of a large institute.

Cogentech has worked with 11 distinct consortium partners spanning 5 countries, a reasonable network breadth for a two-project SME. Their MSCA-RISE participation implies international staff exchanges and direct links to non-EU partners, giving them a wider reach than their modest EC funding suggests.

What sets them apart

Cogentech is one of very few Italian private SMEs with a "società benefit" (benefit corporation) charter operating at the intersection of commercial genomics services and frontier cancer research — their campus proximity to IFOM (a top-tier European cancer biology institute in Milan) gives them access to research infrastructure and talent unusual for a company of their size. Their specific combination of peptide nucleic acid chemistry and circulating RNA profiling for liquid biopsy is a narrow but high-value niche, as PNA-based probes offer superior binding specificity compared to standard DNA probes. For a consortium builder, they offer the rare advantage of an SME that can deliver research-grade genomic analysis with commercial reliability and a defined social mission.

Highlights from their portfolio

• diaRNAgnosis
  Their only directly funded project (EUR 55,200 via MSCA-RISE), it is the clearest expression of their core technology — a platform for profiling circulating cell-free RNA for non-invasive cancer diagnosis using PNA-based microsphere sensors.
• TARGET
  Being included as a third party in an ERC Advanced Grant — one of Europe's most competitive and prestigious individual research grants — signals that a leading PI judged Cogentech's genomics capabilities worth embedding directly into a top-tier research programme.